URGN stock forecast, quote, news & analysis
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more
Why UroGen Pharma (URGN) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- URGN shares fell roughly 19% over the trailing 30 days, from about $43.25 in mid-September to around $35, marking a sharp pullback from an August peak near $50.
- The decline reflects profit-taking after a strong run rather than a single negative clinical or regulatory event; the year-to-date gain remained substantial even after the pullback.
- The most pronounced single-session drop (about 12% on October 8) occurred on unusually light volume, which analysts attributed to technical selling rather than company-specific news.
- The U.S. FDA accepted UroGen's New Drug Application for UGN-103 with a PDUFA target action date of June 14, 2027, a milestone that drew a muted market response.
- Wall Street remains broadly constructive, with a consensus "Moderate Buy" rating and price targets well above the current share price.
UroGen Pharma (URGN) Company Overview and Market Position
UroGen Pharma Ltd. is a commercial-stage biotechnology company focused on urothelial and specialty cancers. Headquartered in Princeton, New Jersey, with operations in Israel, the company has built its business around RTGel, a proprietary reverse-thermal hydrogel technology that enables sustained drug exposure in the urinary tract.
UroGen markets two approved products: JELMYTO, approved in 2020 for low-grade upper tract urothelial cancer, and ZUSDURI (mitomycin) for intravesical solution, approved in June 2025 for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Both treatments deliver mitomycin directly into the bladder or upper urinary tract, offering a non-surgical alternative to repeated transurethral resection. The company's pipeline includes UGN-103, a next-generation mitomycin formulation now under FDA review, as well as UGN-104, UGN-301, and UGN-501 in earlier development stages.
UroGen Pharma (URGN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, URGN declined approximately 19%, from a closing price of $43.25 on September 18 to roughly $35. The move was punctuated by a steep single-day drop of about 12% on October 8, when shares fell from $40.70 to the mid-$36 range on very light trading volume.
The trailing three-month picture has been more volatile. Shares rallied strongly through August, reaching a closing high near $50 on August 19, before giving back much of that advance. As a result, URGN sits roughly 30% below its August peak and about 15% below its mid-July level of roughly $41, even though it remains significantly higher on a year-to-date basis.
What Drove URGN Stock Price in the Last 30 Days
The recent decline appears driven primarily by profit-taking and thin trading conditions rather than a fundamental deterioration in the business. After more than doubling off its 52-week low and climbing roughly 57% year-to-date, URGN entered a consolidation phase, leaving the stock vulnerable to selling pressure.
The October 8 slide stands out because no clear catalyst accompanied it. Multiple market sources noted that volume that day fell roughly 88% below the average daily level, and no material company announcement, SEC filing, or analyst action explained the move. Analysts characterized the drop as low-volume profit-taking following the stock's extended run.
Separately, routine insider activity added to the cautious tone. UroGen's chief financial officer filed to sell a small number of shares in early October to cover tax-withholding obligations, and insider selling totaled roughly $3 million over the trailing 90 days. On the regulatory front, the FDA's October 19 acceptance of the UGN-103 application was a genuine milestone, but the shares traded lower on the news, reflecting how much of the pipeline progress was already priced in.
What Drove URGN Stock Performance Over the Last Quarter
The quarter's broader narrative was defined by the rapid commercial ramp of ZUSDURI and the subsequent digestion of those gains. In its second-quarter report, UroGen delivered revenue of $72.5 million, exceeding Wall Street estimates, with ZUSDURI contributing $50.4 million, a 73% sequential increase. Gross margin reached about 91%, and the company narrowed its quarterly net loss, though earnings per share slightly missed consensus.
That launch momentum, combined with the August submission of the UGN-103 application and a patent allowance extending franchise protection, powered the rally toward $50. Analysts responded with a series of price-target increases, including H.C. Wainwright's raise to $75 and Guggenheim's raise to $58. As the quarter progressed, however, investors weighed the stock's premium valuation, insider selling, and the fact that UGN-103 is a successor to UroGen's own ZUSDURI rather than an expansion into a new market, contributing to the pullback.
Trending AI Robots
For traders looking to supplement their own research with automated, data-driven strategies, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading tools. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary considerably in trading strategy, holding timeframe, and performance metrics, allowing users to explore approaches that range from short-term technical signals to longer-horizon patterns. The section is designed to help investors identify strategies that align with their own objectives and risk tolerance. Exploring the featured bots can offer a useful, automated complement to traditional fundamental analysis.
URGN Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on UroGen's upcoming quarterly results as the clearest near-term check on ZUSDURI's commercial trajectory, including revenue growth, prescriber adoption, and repeat-use trends. The UGN-103 regulatory review, with a PDUFA target action date of June 14, 2027, represents a key medium-term catalyst, as approval would position UroGen to transition the franchise to a newer formulation with extended intellectual-property coverage.
Other factors worth monitoring include progress on UGN-104 and UGN-501 clinical programs, the path toward profitability and cash-flow management, and the April 2027 expiration of JELMYTO's orphan drug exclusivity, which could eventually introduce competitive pressure. Broader biotech sentiment, financing conditions, and any changes in analyst ratings or price targets will also influence trading. These considerations are informational and should not be read as investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
URGN in downward trend: price dove below 50-day moving average on September 18, 2026
URGN moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In 69 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for URGN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for URGN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-12.734) is normal, around the industry mean (3.035). P/E Ratio (-17.508) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (11.403) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapies for urological pathologies
Industry Biotechnology